精氨酸-甘氨酸-天冬氨酸肽/肝素复合涂层在钛表面改性的研究  

Surface modification of titanium with Arg-Gly-Asp peptides/heparin multilayers

作　　者：刘成珪[1] 叶巍[1] 魏战杰[1] 汪洋[1] 张凯伦[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院心血管外科,武汉430022

出　　处：《中华实验外科杂志》2014年第8期1681-1683,共3页Chinese Journal of Experimental Surgery

基　　金：国家高技术研究发展计划（863计划）资助项目（2007AA027Z439）

摘　　要：目的 利用层层自组装技术,在钛表面构建精氨酸-甘氨酸-天冬氨酸（RGD）肽/肝素复合涂层,提高其血液相容性,探讨该技术在人工材料表面改性领域的应用前景.方法 采用层层自组装技术,在预处理的钛试件表面构建RGD肽/肝素复合涂层;对钛表面涂层进行物理表征分析,评价其体内外血液相容性.结果 RGD肽/肝素复合涂层的体外溶血率为0.76％,该涂层可延长部分活化凝血酶原时间到（24.5±0.6）s,减少纤维蛋白原的吸附,减少血小板的黏附与激活,体内动物实验证实该涂层可减少表面血栓形成.结论 利用层层自组装技术形成的RGD肽/肝素复合涂层血液相容性高,有望成为一种新型的生物化钛表面.Objective Arg-Gly-Asp （RGD） peptide/heparin multilayers were coated on pure titanium using a layer-by-layer self-assemble technique,to improve the cytocompatibility of titanium and explore its application in the area of medical metal surface modification.Methods RGD peptide/heparin multilayers were coated on the treated titanium surface.The physical properties of the coating on the titanium surface were analyzed.The in vitro and in vivo blood compatibility of the multilayers was evaluated.Results The ratio of hemolysis of RGD peptide/heparin multilayers was 0.76％,and RGD peptide/heparin multilayers could prolong activated partial thromboplastintime （APTT） to （24.5 ± 0.6） s,and reduce the amount of fibrinogen,and lessen platelet adhesion and activation.It was further confirmed that RGD peptide/heparin multilayers could reduce the surface thrombus formation in the in vivo animal experiment.Conclusion The blood compatibility of pure titanium can be improved significantly after being coated with RGD peptide/heparin multilayers.

关 键 词：钛 精氨酸-甘氨酸-天冬氨酸肽 肝素 自组装 血液相容性 

分 类 号：R318.08[医药卫生—生物医学工程]